In-Depth Focus From ACAAI 2019: Asthma

Using Electronic Health Records to Predict Mortality Post COPD Hospitalization

By

Sheila Jacobs

Publish Date May 9, 2022

For COPD, can electronic health record data predict 90-day post hospitalization mortality — and thereby serve as a risk stratification tool?

Omalizumab Reduces Asthma Exacerbations Across Airway Reversibility Subgroups

By

Brandon May

Publish Date November 22, 2019

Treatment with omalizumab may reduce exacerbations of asthma in patients in several different airway reversibility subgroups.

Worsening of Disease Common in Asthma Prior to Biologic Therapy Initiation

By

Britt Gambino

Publish Date November 22, 2019

Patients who began biologic treatment for asthma tended to have more progressive worsening of disease in the previous 2 years

Benralizumab Does Not Cause Changes in Weight, Blood Pressure in Severe Asthma

By

Brandon May

Publish Date November 22, 2019

Benralizumab does not induce changes in weight or blood pressure when administered for up to 1 year in patients with severe asthma.

Mometasone Furoate-Formoterol Improves Lung Function in Pediatric Asthma

By

Britt Gambino

Publish Date November 22, 2019

The addition of formoterol to mometasone furoate was well tolerated and provided significant improvement in lung function in children compared with mometasone furoate alone.

Benralizumab Associated With Improvements in SGRQ Scores in Asthma

By

Pulmonology Advisor Contributing Writer

Publish Date November 22, 2019

In patients with asthma, benralizumab is associated with substantial improvements in total scores on the St. George’s Respiratory Questionnaire.

Omalizumab Response Similar Across Number, Type of Allergens in Allergic Asthma

By

Britt Gambino

Publish Date November 22, 2019

Response to omalizumab was similar regardless of the number and type of sensitizing allergens in patients with allergic asthma.